Indivina (Medroxyprogesterone Acetate, Estradiol Valerate)

Medroxyprogesterone acetate activates progesterone receptors, providing progestogenic effects that protect the uterine lining. Estradiol valerate is converted to estradiol, which binds estrogen receptors throughout the body, alleviating vasomotor symptoms and supporting bone metabolism. The combination mimics the natural estrogen‑progestogen ratio.

The specific dose and dosing schedule of Indivina are determined by the prescribing clinician based on the individual’s age, health status, and therapeutic goals. Patients should follow the prescriber’s instructions and not alter the dose without medical advice.

Indivina is contraindicated in pregnancy because the hormones can affect fetal development. It is also not recommended during breastfeeding, as estrogen and progestogen can pass into breast milk and may influence milk production. Women who are pregnant, planning pregnancy, or nursing should discuss alternatives with their healthcare provider.

To order Indivina, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Indivina provides a fixed‑dose combination of medroxyprogesterone acetate and estradiol valerate, offering convenience over separate estrogen and progestogen tablets. Compared with estradiol‑only products, it includes progestogen to protect the endometrium in women with an intact uterus, reducing the need for additional medication.

Indivina tablets should be stored at ambient temperature, below 25 °C. Keep them in the original container, protect from moisture, heat, and direct sunlight. Do not store in the bathroom or near a kitchen sink to maintain product stability.

Indivina is taken orally, usually once daily as directed by a healthcare professional. The tablet should be swallowed whole with water and can be taken with or without food, unless the prescriber advises otherwise.

The most serious risks include venous thromboembolism, stroke, myocardial infarction, liver dysfunction, gallbladder disease, and an increased risk of estrogen‑dependent cancers such as breast cancer. Patients should be monitored for signs of clotting, liver issues, or unusual pain and report any concerns promptly.

Indivina should not be used by women with a history of thromboembolic disorders, active or past estrogen‑dependent cancers, uncontrolled hypertension, severe liver disease, or known hypersensitivity to medroxyprogesterone acetate or estradiol. It is also contraindicated during pregnancy and breastfeeding.